It is well established that before a medical specialist can perform surgery on a patient he must obtain the consent of the patient, if the patient is capable of performing the operation, or of someone legitimately sanctioned to give consent for the patient, unless timely intervention is important to spare the patient's life or health (XXX). There are two parts of consent associated with any surgical event and the assumption used to address a reason for movement based on an absence of consent is contingent on the extent of consent in question. The battery was created ahead of schedule as an appropriate reason for an activity in which a doctor does not obtain the consent of the tolerator for an operation or, after accepting a type of medicine, performs an alternative treatment for which it was not given consent. The Cobbs court agreed with the decisions that held that the reason for battery activity was an adequate hypothesis for recovery when such consent was not acquired. A secondary element of informed consent concerns the assumption that the consent actually given is informed consent. Before the operation, the specialist should enlighten his patient about the evolution of the disease, the style of the operation, the possible dangers involved and the feasible choices, so that the patient can carefully choose whether to undergo the operation. The necessary consent has been called "educated" consent. Allegations of a doctor's failure to satisfactorily disclose the dangers and plan B of proposed drugs date back half a century and have been rapidly reproduced over the past decade. In any case, there was no consistency between the local offices in choosing the correct hypothesis of recovery. Aga activity... half of the document... non-Hodgkin's lymphoma treated uniformly and receiving intrathecal central nervous system. prophylaxis: a GELA study on 974 patients. Ann Oncol 2000; 685–690. Bos GM, Van Putten WL, Van der Holt B et al. For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory? Ann Oncol 1998; 9:191–194. Zinzani PL, Magagnoli M, Frezza G et al. Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: the experience of Bologna Leuk Lymphoma 1999; , Lepage E, Coiffier B et al. A randomized comparison of ACVBP and CHOP in the treatment of advanced aggressive non-Hodgkin's lymphoma: LNH93-5 Blood 2000: 832a (Abstr 3596) study. Rubenstein JL, Combs D, Rosenberg; J et al. Rituximab therapy for central nervous system lymphomas: targeted to the leptomeningeal compartment. Blood 2003; 101: 466–468.